首页> 中文期刊> 《天津医药》 >ADAM17-siRNA抑制人MCF-7乳腺癌细胞体外侵袭能力的研究

ADAM17-siRNA抑制人MCF-7乳腺癌细胞体外侵袭能力的研究

             

摘要

Objective: To investigate the effect of a disintegrin and metalloproteinase 17 (ADAM17)-siRNA on the invasion of human MCF-7 breast cancer cells. Methods: ADAM17-siRNA was transfected into MCF-7 breast cancer cells mediated by oligofectamine. ADAM17 mRNA and protein expressions were detected by real-time PCR and Western blot respectively, and the invasive ability of MCF-7 cells was studied by Transwell method. Results: ADAM17 mRNA and protein showed higher expression in MCF-7 cells, while it was significantly decreased with ADAM17 siRNA treatment. Furthermore, the invasive ability of MCF-7 cells was markedly inhibited by ADAM17 siRNA. Conclusion: ADAM17 plays an important role in the invasion of MCF-7 breast cancer cells, and ADAM17-siRNA can inhibit the invasive ability of MCF-7 cells by blocking the expression of ADAM17.%目的:观察人MCF-7乳腺癌细胞中解聚素-金属蛋白酶17(ADAM17)的表达受抑制后对肿瘤细胞体外侵袭能力的影响.方法:构建可以表达针对ADAM17的小干扰RNA(siRNA)的干涉载体,转染人乳腺癌细胞系MCF-7.利用real-time PCR法检测肿瘤细胞内ADAM17 mRNA的表达水平,Western blot法检测ADAM17蛋白的表达,Transwell方法检测肿瘤细胞的体外侵袭能力.结果:ADAM17mRNA及蛋白在MCF-7细胞中呈高表达,转染特异性ADAM17-siRNA后,其表达显著被抑制,同时细胞的体外侵袭能力也明显受到抑制.结论:ADAM17及特异性的siRNA有望成为抗肿瘤侵袭治疗的新方法.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号